The Dish’s Weekly Biotechnology News Wrap Up – July 24, 2015

This week’s biotechnology news headlines include, pharma drug profits, Alzheimer’s drug candidate, Ebola treatment, BMS receives breakthrough designation for HIV candidate, Janssen launching pilot study with Forge Therapeutics, BMS’ Opdivo for kidney cancer, and new antibodies for Alzheimer’s and Parkinson’s.



Cell Culture Events


High Performance Tour 2015

Discover how to improve efficiency and productivity for your bioprocessing workflows during our exclusive High Performance Tour.

Learn how the choice of chromatography media (resins), hardware, and services can dramatically affect your process performance.

Register now to reserve your seat at this special event where you can gain insights in improved process efficiency and productivity.

Coming to these Cities:

  • San Diego, CA – September 15, 2015
  • San Francisco, CA – September 17, 2015

To Register –





  • Bioproduction – October 14-15, 2015 – Dublin, Ireland – technological developments and explore best practices in biomanufacturingThe biopharmaceutical industry is making a capital investment of approximately $8 billion in new facilities in Ireland, most of which has come in the last 10 years, representing close to the biggest wave of investment in new biotech facilities anywhere in the world.Join us at BioProduction 2015 in Dublin this October to see why so much is being invested in this area and to network with leading players within this growing industry!BioProduction 2015: Europe’s leading and largest event for a comprehensive update on all aspects of large scale biological manufacturing. Providing insights on the latest technologies, upstream/downstream processing, process analytics, the implementation of continuous manufacturing, facility design, flexibility facilities and single use systems to reduce inefficiencies during the biomanufacturing process.4 Conferences – 1 Exhibition – 1 Congress
    • Conference 1: Continuous Manufacturing
    • Conference 2: Upstream Processing – Production, Development & Analytics
    • Conference 3: Manufacturing Strategy & Technology
    • Conference 4: Downstream Processing

    For more information on the 2015 event please visit the event website at

  • Bioprocessing International – October 26-29, 2015 Hynes Convention Center Boston, MA


“A Not-So-Transparent Attempt to Cap Drug Prices,” The Wall Street Journal

“At the dawn of the 20th century, life expectancy in the United States was 47 years. Today, it’s 79. Two decades ago, a diagnosis of HIV/AIDS or hepatitis C was a death sentence. The mortality rate from AIDS has since dropped 85%, to fewer than 7,000 deaths a year from 44,000. Hepatitis C cure rates have reached 90%.”

If you like this story, please see our blog titled “Continuous Bioprocessing – The Biomanufacturing Model of the Future?”

“Lilly says drug slows Alzheimer’s in patients with mild disease,” Reuters

“Patients with mild Alzheimer’s disease who took Eli Lilly and Co’s experimental drug solanezumab early in the course of their disease preserved more of their cognitive and functional ability, according to new Lilly data released on Wednesday.”

If you like this story, please see our blog titled “Is Now the Time to Move Your Research to 3D Cell Culture? Key Considerations and New Tools to Ensure Success

“Biotech company to manufacture Ebola treatment in Baltimore,” The Washington Times

“A biotechnology company has announced that a drug that could cure patients of the Ebola virus will be manufactured at its Baltimore facility.”

If you like this story, please see our blog titled “2014 FDA New Drug Approvals – 11 Biologics Receive Approval

“Bristol-Myers Squibb Receives Breakthrough Designation for HIV Treatment,” The Wall Street Journal

“Bristol-Myers Squibb Co. said Tuesday that the U.S. Food and Drug Administration has granted breakthrough designation for its HIV treatment for users who have become accustomed to most other treatment options.”

If you like this story, please see our blog titled “3D Bioprinting – Research Successes, Challenges, and Future Possibilities

“Janssen R&D Launching Pilot Study with Forge Therapeutics,” Genetic Engineering News

“Johnson & Johnson’s Janssen Research & Development (JRD) unit will fund a pilot study of Forge Therapeutics’ chemistry platform in the discovery of new drugs based on metalloprotein inhibitors.”

If you like this story, please see our blog titled “3D Printing and 3D Bioprinting – Changing the Healthcare Landscape

“Bristol-Myers’ Opdivo found effective in kidney cancer,” Reuters

“Bristol-Myers Squibb Co said a late-stage trial of its drug, Opdivo, was stopped early after the immunotherapy was found to be effective in patients with the most common form of kidney cancer.”

If you like this story, please see our blog titled “Cell Culture Media Optimization: Making the perfect magical potion

“NYU Langone team spotlights new antibodies for Alzheimer’s, Parkinson’s,” Fierce Biotech Research

“With the Alzheimer’s Association International Conference underway in Washington, DC, there’s been a big focus on the late-stage pipeline. But scientists at NYU Langone Medical Center were focused on new animal data that they say supports work on a new group of antibodies that can tackle two of the chief culprits behind the brain-damaging disease.”

If you like this story, please see our blog titled “Cord Blood-derived HSCs – The Quest to Overcome Limited Cell Numbers

Pin It on Pinterest